Merck Serono, the biopharmaceutical business of Merck, and Illumina, Inc., have agreed to work together to expand the development of a universal next-generation sequencing-based oncology
Merck Serono, the biopharmaceutical business of Merck, and Illumina, Inc., have agreed to work together to expand the development of a universal next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies.
Under the deal, the two companies will develop assays that detect and simultaneously measure multiple genetic variants in a single tumor sample. Illumina’s regulatory track record was an important consideration because next-generation sequencing platforms cleared by a regulatory agency can accelerate the development of an assay and facilitate the registration of a companion diagnostic, according to Merck Serono.
“Our collaboration with Illumina around next-generation sequencing will enable us to perform genome studies at a pace unheard of a few years ago, and could lead to the development of several diagnostics,” said Susan Herbert, Head of Global Business Development at Merck Serono. “This collaboration will strengthen the position of Merck Serono as a global leader in precision medicine in oncology.”
The package will include development of the diagnostic, worldwide regulatory approvals, and global commercialization.
“This agreement is another step forward in realizing the promise of precision medicine,” said Richard Klausner, M.D., Illumina’s Chief Medical Officer. “There is a clear need to expand genetically-based clinical trials as a key approach for developing better treatments for cancer.”
This collaboration complements Merck Serono’s existing partnerships in the area of diagnostics, including Life Technologies and Dako. With headquarters in Darmstadt, Germany, the company has brands available in 150 countries that help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.